Previous 10 | Next 10 |
Athersys to continue to provide close support to Healios to advance its ARDS program Athersys, Inc. (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (Healios), has released positive topline data from its ONE-BRIDGE clinical trial evaluating the safe...
Improvements to Collaboration Enhance Preparations for Commercial Activity in Japan Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE Mothers: 4593) jointly announced today an expansion and deepening of their partnership to optimize and better align the collabora...
ATHX did what many biopharma do, they reinvented a failed trial as a success based on post-hoc subgroup analysis. However, the subgroup they chose makes scientific sense. Phase 3 topline data next year will decide the issue. For further details see: Athersys: Subgroup An...
Athersys Inc. (NASDAQ:ATHX) traded today at a new 52-week low of $1.35. So far today approximately 493,000 shares have been exchanged, as compared to an average 30-day volume of 2.3 million shares. Athersys Inc. (NASDAQ:ATHX) is currently priced 6.3% above its average consensus analyst p...
Athersys Inc. (NASDAQ:ATHX) traded at a new 52-week low today of $1.36. This new low was reached on below average trading volume as 493,000 shares traded hands, while the average 30-day volume is approximately 2.3 million shares. Athersys Inc. (NASDAQ:ATHX) is currently priced 6.0% above...
Shares of Athersys Inc. (NASDAQ:ATHX) traded today at $1.38, breaking its 52-week low. Approximately 493,000 shares have changed hands today, as compared to an average 30-day volume of 2.2 million shares. Athersys Inc. has overhead space with shares priced $1.43, or 2.7% below the averag...
koto_feja/iStock via Getty Images Athersys (ATHX) climbed ~10.6% in the pre-market after the company announced the publication of several years’ worth of clinical research on Multipotent Adult Progenitor Cells ((MAPC)), clinically known as MultiStem, in the peer-reviewed journal Scient...
Athersys, Inc. (NASDAQ: ATHX) announced today that data accumulated from several years of preclinical research was published in the peer-reviewed journal Scientific Reports . The publication describes the findings from extensive in vitro studies investigating the role Multipoten...
Athersys' MultiStem lead ischemic stroke indication is struggling with pandemic-induced slowdowns to complete trials in the US and Japan. Athersys' runner-up indication, MultiStem in the treatment of ARDS, is moving apace. Athersys' financial condition is challenging. Th...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q1 2021 Earnings Call May 06, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q1 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...